guest ::
| Home > Publications database > Beyond angiogenesis: Exploiting angiocrine factors to restrict tumor progression and metastasis. > print |
| Home > Publications database > Beyond angiogenesis: Exploiting angiocrine factors to restrict tumor progression and metastasis. > print |
| 001 | 148771 | ||
| 005 | 20240229123034.0 | ||
| 024 | 7 | _ | |a 10.1158/0008-5472.CAN-19-3351 |2 doi |
| 024 | 7 | _ | |a pmid:31831463 |2 pmid |
| 024 | 7 | _ | |a 0008-5472 |2 ISSN |
| 024 | 7 | _ | |a 0099-7013 |2 ISSN |
| 024 | 7 | _ | |a 0099-7374 |2 ISSN |
| 024 | 7 | _ | |a 1538-7445 |2 ISSN |
| 024 | 7 | _ | |a altmetric:72711639 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2019-03284 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Singhal, Mahak |0 P:(DE-He78)1956b17ee4a34a5fdd72287aca7cdc0a |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Beyond angiogenesis: Exploiting angiocrine factors to restrict tumor progression and metastasis. |
| 260 | _ | _ | |a Philadelphia, Pa. |c 2020 |b AACR |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1601532542_4249 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a DKFZ-ZMBH Alliance 2020 Feb 15;80(4):659-662#EA:A190#LA:A190# |
| 520 | _ | _ | |a Looking beyond tumor angiogenesis, the past decade has witnessed a fundamental change of paradigm with the discovery that the vascular endothelium does not just respond to exogenous cytokines, but exerts active 'angiocrine' gatekeeper roles controling their microenvironment in an instructive manner. While vascular niches host disseminated cancer cells and promote their stemness, endothelial cell-derived angiocrine signals orchestrate a favorable immune milieu to facilitate metastatic growth. Here, we discuss recent advances in the field of tumor microenvironment research and propose angiocrine signals as promising targets of future mechanism-driven anti-metastatic therapies, which may prove useful to synergistically combine with chemotherapy and immunotherapy. |
| 536 | _ | _ | |a 311 - Signalling pathways, cell and tumor biology (POF3-311) |0 G:(DE-HGF)POF3-311 |c POF3-311 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Augustin, Hellmut |0 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b |b 1 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1158/0008-5472.CAN-19-3351 |g p. canres.3351.2019 - |0 PERI:(DE-600)2036785-5 |n 4 |p 659-662 |t Cancer research |v 80 |y 2020 |x 1538-7445 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:148771 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)1956b17ee4a34a5fdd72287aca7cdc0a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-311 |2 G:(DE-HGF)POF3-300 |v Signalling pathways, cell and tumor biology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER RES : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCER RES : 2017 |
| 920 | 2 | _ | |0 I:(DE-He78)A190-20160331 |k A190 |l A190 Vaskuläre Onkologie und Metastatistierung |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)A190-20160331 |k A190 |l A190 Vaskuläre Onkologie und Metastatistierung |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A190-20160331 |k A190 |l A190 Vaskuläre Onkologie und Metastatistierung |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A190-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|